Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
ECC5004/AZD5004 is an investigational oral small molecule GLP-1 receptor agonist licensed to AstraZeneca in November 2023 ECC5004/AZD5004 is an investigational oral small molecule GLP-1 receptor agoni
AstraZeneca Receives CHMP's Approval for Wainzua in Europe
01:56pm, Tuesday, 22'nd Oct 2024
The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
AstraZenca drug for nerve damage given EU Green light
02:59am, Monday, 21'st Oct 2024
AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated am
AZN or NVO: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 14'th Oct 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Wednesday, 09'th Oct 2024
Astrazeneca (AZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin
UK bosses get green light to hike pay from investment body
09:47am, Wednesday, 09'th Oct 2024
Britain's bosses have been given the green light to pay themselves more by their institutional owners Institutional trade body the Investment Association made the call in a new set of guidelines issue
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
02:05pm, Tuesday, 08'th Oct 2024
AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
06:30am, Tuesday, 08'th Oct 2024
Investing in the most popular players in the space isn't the only valid approach.
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
05:05am, Tuesday, 08'th Oct 2024
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching
12:44pm, Monday, 07'th Oct 2024
George Soros is among the most renowned and controversial hedge fund managers on the planet.
5 Large Drug Stocks to Watch From a Thriving Industry
11:00am, Monday, 07'th Oct 2024
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are wo
AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor
10:51am, Monday, 07'th Oct 2024
AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.
AstraZeneca buys licence for cholesterol treatment from China's CSPC
07:52am, Monday, 07'th Oct 2024
AstraZeneca PLC (LSE:AZN) shares got a small boost as the UK's largest pharma company snapped up a licence for a drug that could lower in the bloodstream, paying $100 million initially. The FTSE 1
AstraZeneca to pay up to $2 billion to license cardiovascular drug
04:58am, Monday, 07'th Oct 2024
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC
04:53am, Monday, 07'th Oct 2024
AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
